Groups urge Fed Circ to rehear Biogen patent case

Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

5 May 2026 J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.

Americas

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

4 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.

Americas

Brussels under scrutiny for IP policy as US flags risks to innovation

1 May 2026 The Office of the US Trade Representative has placed the EU on its Watch List, outlining concerns about pharma legislation, GIs and digital copyright.

More features

US judge allows rare patent defence in ‘world’s smallest heart pump’ suit

WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

Brussels under scrutiny for IP policy as US flags risks to innovation

Squire Patton Boggs promotes partner to head Europe IP&T practice

From the courtroom: Hikma v Amarin SCOTUS oral arguments

Report: 85% of in-house counsel want IP service providers to embrace AI

Moderna loses key mRNA patent in European vaccine fight

Groups urge Fed Circ to rehear Biogen patent case

More on this story

Editor's picks

Editor's picks

More features